An Introduction to ACR Response Criteria in Rheumatoid Arthritis Clinical Trials [Video]

ACR response criteria in rheumatoid arthritis clinical trials help classify whether a patient has improved between baseline and a later visit. In this explainer, we break down how ACR20, ACR50 and ACR70 work, why the responder output depends on several component measures, and where endpoint planning, data quality and visit timing can affect interpretation.

WHAT THIS VIDEO COVERS
• What ACR20 measures in rheumatoid arthritis trials
• How tender and swollen joint counts affect responder classification
• The supporting measures used alongside joint counts
• How ACR50 and ACR70 relate to ACR20
• Why a single landmark visit may not tell the full response story
• Practical risks around missing data, lab turnaround and visit windows

ACR endpoints can look straightforward once they are reported as responder or non-responder, but the derivation depends on clean, timely and consistent component data. Treating ACR as a composite endpoint helps teams protect the measures that matter most and decide early whether the time profile of response needs to be part of the analysis.

At Quanticate, our clinical data management, statistical programming and biostatistics teams support sponsors with practical, rigorous support across clinical trials and regulated development.